Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.95 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | NPC1 | O15118 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 2/20 | 0.79 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.79 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.64 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.61 |
| ▸ | CDK9 | P50750 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetanilide SCHEMBL16922180 | 0.97 | NAPRT (1.00) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL3359084 | 0.97 | NAPRT (1.00) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL24681 | 0.97 | NAPRT (1.00) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL1332076 | 0.97 | NAPRT (1.00) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| SCHEMBL19669626 | 0.97 | NAPRT (1.00) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL11511638 | 0.95 | NAPRT (0.95) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL5883953 | 0.95 | NAPRT (0.95) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL5883922 | 0.95 | NAPRT (0.95) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL5049604 | 0.95 | NAPRT (0.95) | NAPRTHSD17B10MAPTKMT2ANPC1 | |
| Acetanilide SCHEMBL11207565 | 0.95 | NAPRT (0.95) | NAPRTHSD17B10MAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809323-B2 | Therapeutic applications of pro-apoptotic benzodiazepines | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-19 | — | — | US | disclosed |
| US-8722667-B2 | Compositions and methods for inhibiting the proliferation of cells | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140038947-A1 | THERAPEUTIC APPLICATIONS OF PRO-APOPTOTIC BENZODIAZEPINES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-02-06 | — | — | US | disclosed |
| US-20130190300-A1 | COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF CELLS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-07-25 | — | — | US | disclosed |
| US-8415343-B2 | Autoimmune diseases; antiinflammatory agents; antiproliferative agents; benzodiazepine compound | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2062583-B1 | Therapeutic applications of pro-apoptotic benzodiazepines | UNIV MICHIGAN (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120165301-A1 | BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-28 | — | — | US | disclosed |
| US-8168626-B2 | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2359831-A2 | Therapeutic applications of pro-apoptotic benzodiazepines | The Regents of the University of Michigan (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100222310-A1 | BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-02 | — | — | US | disclosed |
| EP-1398033-A2 | Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1143946-B1 | USE OF BENZODIAZEPINES FOR TREATING AUTOIMMUNE DISEASES INDUCED BY APOPTOSIS | UNIV MICHIGAN (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030119029-A1 | Compositions and methods relating to novel benzodiazepine compounds and targets thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2003-06-26 | — | — | US | disclosed |
| WO-2003015703-A2 | COMPOSITIONS AND METHODS RELATING TO NOVEL BENZODIAZEPINE COMPOUNDS AND TARGETS THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2003-02-27 | — | — | WO | disclosed |
| WO-2000066106-A9 | USE OF BENZODIAZEPINES FOR TREATING AUTOIMMUNE DISEASES INDUCED BY APOPTOSIS | UNIV MICHIGAN (US) | 2002-04-18 | — | — | WO | disclosed |
| EP-1143946-A2 | USE OF BENZODIAZEPINES FOR TREATING AUTOIMMUNE DISEASES INDUCED BY APOPTOSIS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2001-10-17 | — | — | EP | disclosed |
| US-20010016583-A1 | Therapeutic application of pro-apoptotic benzodiazepines | GLICK GARY D (US) | 2001-08-23 | — | — | US | disclosed |
| WO-2000066106-A2 | USE OF BENZODIAZEPINES FOR TREATING AUTOIMMUNE DISEASES INDUCED BY APOPTOSIS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2000-11-09 | — | — | WO | disclosed |
| US-4252977-A | Novel acetamide compounds and process for producing them | GENERAL ELECTRIC COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| US-4101465-A | TO POLYISOCYANURATES, ALKALI METAL GLYCINE SALTS, QUATERNARY AMMONM CARBOXYLATES, ALKALI METAL SALTS OF AMIDES AND ACIDS | THE UPJOHN COMPANY (US) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190300-A1 | COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF CELLS | BAX, BCL2, MKI67 | NAPRT 3541/4885HSD17B10 2076/4885MAPT 2082/4885 |
| US-20100222310-A1 | BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS | VDR, CYP2R1, CYP24A1 | NAPRT 3442/4885HSD17B10 245/4885MAPT 968/4885 |
| US-20120165301-A1 | BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS | VDR, CYP2R1, CYP24A1 | NAPRT 3462/4885HSD17B10 254/4885MAPT 985/4885 |
| US-20030119029-A1 | Compositions and methods relating to novel benzodiazepine compounds and targets thereof | GABRB1, GABRB3, GABRB2 | NAPRT 3629/4885HSD17B10 1482/4885MAPT 1687/4885 |
| US-20140038947-A1 | THERAPEUTIC APPLICATIONS OF PRO-APOPTOTIC BENZODIAZEPINES | BAD, GABRA5, GABRB1 | NAPRT 4425/4885HSD17B10 1118/4885MAPT 4127/4885 |
| US-20010016583-A1 | Therapeutic application of pro-apoptotic benzodiazepines | BAD, BAK1, GABRA5 | NAPRT 4525/4885HSD17B10 1243/4885MAPT 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.